CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
23 Apr 2024: Tharimmune Enters Option Agreement for Crucial Technologies in HER2/HER3 Antibody Drug Conjugates
- Tharimmune, Inc. secures an option agreement for an exclusive license with Washington University for the technology of antibodies targeting human HER2
- Tharimmune’s multi-specific technology targets HER2 and HER3, pivotal in promoting cancer cell growth, aiming to advance novel treatments against HER2, a key tumor target
- The company aims to develop antibodies overlapping with different epitopes on HER2, potentially complementing existing therapies and affecting novel conformational epitopes important in tumor cell signaling
- This agreement enhances Tharimmune’s internal early-stage pipeline and complements their efforts in developing novel antibodies with ultra-long CDR3 domains
- These antibodies may provide access to previously hidden or inaccessible epitopes, potentially leading to more efficient targeting of multiple cell surface portions
